Kestra Medical Technologies (KMTS) grants 25,227 RSUs to director

Rhea-AI Filing Summary

Umberger Traci S reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies director and officer Traci S. Umberger received a grant of 25,227 restricted stock units (RSUs). These RSUs entitle her to one common share per unit upon settlement and will vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to continued service. Following this equity award, her direct holdings increased to 161,860 common shares, reflecting routine stock-based compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Umberger Traci S

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	25,227	$0.00	--

Holdings After Transaction: Common Shares — 161,860 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 25,227 RSUs Post-grant holdings: 161,860 shares Grant price per share: $0.00 per share +1 more

4 metrics

RSU grant size 25,227 RSUs Equity award to Traci S. Umberger on June 3, 2026 vesting schedule reference

Post-grant holdings 161,860 shares Total common shares held directly after RSU grant

Grant price per share $0.00 per share Compensation grant, not open-market purchase

Vesting schedule 1/3 each year over 3 years Anniversaries of June 3, 2026, subject to continued service

Key Terms

restricted stock units ("RSU"), vest over three years, anniversary of June 3, 2026

3 terms

restricted stock units ("RSU") financial

"Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share"

vest over three years financial

"Subject to the Reporting Person's continued service, the RSUs will vest over three years"

anniversary of June 3, 2026 financial

"with 1/3 vesting on each anniversary of June 3, 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Umberger Traci S

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/03/2026		A		25,227(1)	A	$0	161,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Remarks:

General Counsel and Chief Adminstrative Officer

	/s/ Traci S. Umberger	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Traci S. Umberger receive in the latest Kestra (KMTS) Form 4?

Traci S. Umberger received a grant of 25,227 restricted stock units from Kestra Medical Technologies. Each RSU represents the right to receive one common share at settlement, forming part of her stock-based compensation package as a director and officer.

How do the 25,227 RSUs granted to Kestra (KMTS) director Traci Umberger vest?

The 25,227 RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026. Vesting is conditioned on Traci Umberger’s continued service with Kestra Medical Technologies throughout this three-year period.

Is the Kestra (KMTS) Form 4 transaction an open-market buy or sell?

The Form 4 reports a grant of RSUs, not an open-market buy or sell. The transaction code “A” indicates a grant or award, meaning the shares were awarded as compensation rather than purchased or sold in the market.

What are Traci Umberger’s Kestra (KMTS) holdings after the RSU grant?

After the RSU grant, Traci Umberger’s direct holdings total 161,860 common shares. This figure includes the impact of the 25,227 RSUs reported in the filing and shows her overall equity position associated with Kestra Medical Technologies after the award.

What conditions apply to the Kestra (KMTS) RSUs granted to Traci Umberger?

The RSUs require Traci Umberger’s continued service with Kestra Medical Technologies to vest. One-third of the 25,227 RSUs will vest on each anniversary of June 3, 2026, aligning the award with ongoing employment over three years.